{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:02:26Z","timestamp":1792414946358,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ivermectin is lethal to <jats:italic>Anopheles<\/jats:italic> mosquitoes and a novel approach to malaria transmission control. Ivermectin could be co-administered with antimalarial drugs in mass drug administration, seasonal malaria chemoprevention, or other chemoprevention approaches. Co-administration with antimalarial drugs may impact ivermectin metabolism and\/or absorption, resulting in increased or decreased exposure to ivermectin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>To evaluate potential CYP-mediated drug-drug interactions (DDIs), ivermectin (1\u00a0\u00b5M) was incubated with pooled human liver microsomes, with and without the most commonly used antimalarial drugs at concentrations approximating twofold to tenfold the peak concentrations achieved following standard treatment. The antimalarial drugs investigated were dihydroartemisinin, piperaquine, chloroquine, artesunate, pyronaridine, mefloquine, artemether, lumefantrine, primaquine, atovaquone, proguanil, tafenoquine, sulfadoxine, pyrimethamine, and amodiaquine. Samples (50 \u00b5L) were collected at 0, 15, 30, 45, 60, 90, 120, and 150\u00a0min of incubation and ivermectin concentrations were measured using liquid chromatography-mass spectrometry. The metabolism rate of ivermectin was evaluated based on the normalized peak area (%) of ivermectin over a total of 150\u00a0min of incubation, applying linear regression to derive the rate of metabolism. Antimalarial compounds resulting in notable impact on the rate of ivermectin metabolism with a relative difference\u2009\u2265\u200950% and\u2009\u2265\u200925% were considered to have a substantial and partial effect on the in vitro metabolism of ivermectin, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Compounds that had a substantial DDI effect on the in vitro metabolism of ivermectin included piperaquine (98%), mefloquine (91%), chloroquine (76%), proguanil (60%), and lumefantrine (51%). Compounds that a partial DDI effect on the in vitro metabolism of ivermectin included atovaquone (48%), artesunate (27%), and pyronaridine (25%). All other antimalarials evaluated showed an in vitro interaction of 8\u201323%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Several of the commonly used antimalarial drugs, are mostly or in part metabolized by CYP3A4 and showed a notable DDI effect on the in vitro metabolism of ivermectin. This could potentially lead to clinically important pharmacokinetic and pharmacodynamic DDIs if co-administered, and needs to be evaluated in prospective clinical trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12936-025-05516-1","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:41:18Z","timestamp":1758739278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of in vitro drug-drug interactions of ivermectin and antimalarial compounds"],"prefix":"10.1186","volume":"24","author":[{"given":"Phornpimon","family":"Tipthara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattawan","family":"Kullasakboonsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Kobylinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"5516_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4269\/ajtmh.19-0620","volume":"102","author":"P Billingsley","year":"2020","unstructured":"Billingsley P, Binka F, Chaccour C, Foy B, Gold S, Gonzalez-Silva M, et al. A roadmap for the development of ivermectin as a complementary malaria vector control tool. Am J Trop Med Hyg. 2020;102:3\u201324.","journal-title":"Am J Trop Med Hyg"},{"key":"5516_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1473-3099(18)30163-4","volume":"18","author":"M Smit","year":"2018","unstructured":"Smit M, Ochomo E, Aljayyoussi G, Kwambai T, Abong\u2019o B, Chen T, et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18:615\u201326.","journal-title":"Lancet Infect Dis"},{"key":"5516_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/cpt.1716","volume":"107","author":"K Kobylinski","year":"2020","unstructured":"Kobylinski K, Jittamala P, Hanboonkunupakarn B, Pukrittayakamee S, Pantuwattana K, Phasomkulsolsil S, et al. Safety, pharmacokinetics, and mosquito-lethal effects of ivermectin in combination with dihydroartemisinin-piperaquine and primaquine in healthy adult Thai subjects. Clin Pharmacol Ther. 2020;107:1221\u201330.","journal-title":"Clin Pharmacol Ther"},{"key":"5516_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/cid\/ciu797","volume":"60","author":"A Ou\u00e9draogo","year":"2015","unstructured":"Ou\u00e9draogo A, Bastiaens G, Tiono A, Guelb\u00e9ogo W, Kobylinski K, Ou\u00e9draogo A, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis. 2015;60:357\u201365.","journal-title":"Clin Infect Dis"},{"key":"5516_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(21)00557-0","volume":"22","author":"E Dabira","year":"2022","unstructured":"Dabira E, Soumare H, Conteh B, Ceesay F, Ndiath M, Bradley J, et al. Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia. Lancet Infect Dis. 2022;22:519\u201328.","journal-title":"Lancet Infect Dis"},{"key":"5516_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1473-3099(24)00580-2","volume":"25","author":"H Hutchins","year":"2025","unstructured":"Hutchins H, Pretorius E, Bradley J, Teixeira da Silva E, Vasileva H, Ndiath M, et al. Adjunctive ivermectin mass drug administration for malaria control on the Bijagos Archipelago of Guinea-Bissau (MATAMAL): a quadruple-blinded, cluster-randomised, placebo-controlled trial. Lancet Infect Dis. 2025;25:424\u201334.","journal-title":"Lancet Infect Dis"},{"key":"5516_CR7","first-page":"eCD008846","volume":"9","author":"M Shah","year":"2021","unstructured":"Shah M, Hwang J, Choi L, Lindblade K, Kachur S, Desai M. Mass drug administration for malaria. Cochrane Database Syst Rev. 2021;9:eCD008846.","journal-title":"Cochrane Database Syst Rev"},{"key":"5516_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1475-2875-13-51","volume":"13","author":"A Kondrashin","year":"2014","unstructured":"Kondrashin A, Baranova A, Ashley E, Recht J, White N, Sergiev V. Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J. 2014;13:51.","journal-title":"Malar J"},{"key":"5516_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161311","volume":"11","author":"A Kuehne","year":"2016","unstructured":"Kuehne A, Tiffany A, Lasry E, Janssens M, Besse C, Okonta C, et al. Impact and lessons learned from mass drug administrations of malaria chemoprevention during the Ebola Outbreak in Monrovia, Liberia, 2014. PLoS ONE. 2016;11: e0161311.","journal-title":"PLoS ONE"},{"key":"5516_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12936-015-0991-x","volume":"14","author":"G Dow","year":"2015","unstructured":"Dow G, Liu J, Lin G, Hetzell B, Thieling S, McCarthy W, et al. Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries. Malar J. 2015;14:473.","journal-title":"Malar J"},{"key":"5516_CR11","volume-title":"Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies","author":"WHO","year":"2011","unstructured":"WHO. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. Geneva: World Health Organization; 2011."},{"key":"5516_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1128\/AAC.03829-14","volume":"59","author":"P Jittamala","year":"2015","unstructured":"Jittamala P, Pukrittayakamee S, Ashley E, Nosten F, Hanboonkunupakarn B, Lee S, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2015;59:505\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"5516_CR13","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.1128\/AAC.01588-16","volume":"60","author":"J Green","year":"2016","unstructured":"Green J, Mohamed K, Goyal N, Bouhired S, Hussaini A, Jones S, et al. Pharmacokinetic interactions between tafenoquine and dihydroartemisinin-piperaquine or artemether-lumefantrine in healthy adult subjects. Antimicrob Agents Chemother. 2016;60:7321\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"5516_CR14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3109\/00498254.2012.693972","volume":"42","author":"T Lee","year":"2012","unstructured":"Lee T, Huang L, Johnson M, Lizak P, Kroetz D, Aweeka F, et al. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012;42:1088\u201395.","journal-title":"Xenobiotica"},{"key":"5516_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1017\/S0031182004006481","volume":"130","author":"R Tripathi","year":"2005","unstructured":"Tripathi R, Awasthi A, Dutta G. Mefloquine resistance reversal action of ketoconazole\u2014a cytochrome P450 inhibitor, against mefloquine-resistant malaria. Parasitology. 2005;130:475\u20139.","journal-title":"Parasitology"},{"key":"5516_CR16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1017\/S0031182011000850","volume":"138","author":"R Tripathi","year":"2011","unstructured":"Tripathi R, Pandey S, Rizvi A. Clarithromycin, a cytochrome P450 inhibitor, can reverse mefloquine resistance in Plasmodium yoelii nigeriensis- infected Swiss mice. Parasitology. 2011;138:1069\u201376.","journal-title":"Parasitology"},{"key":"5516_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1124\/dmd.31.6.748","volume":"31","author":"D Projean","year":"2003","unstructured":"Projean D, Baune B, Farinotti R, Flinois J, Beaune P, Taburet A, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003;31:748\u201354.","journal-title":"Drug Metab Dispos"},{"key":"5516_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2217\/pgs.09.72","volume":"10","author":"R Janha","year":"2009","unstructured":"Janha R, Sisay-Joof F, Hamid-Adiamoh M, Worwui A, Chapman H, Opara H, et al. Effects of genetic variation at the CYP2C19\/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics. 2009;10:1423\u201331.","journal-title":"Pharmacogenomics"},{"key":"5516_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2023.114065","volume":"181","author":"X Zhang","year":"2023","unstructured":"Zhang X, Li Q, Zhou Q, Li Y, Li J, Jin L, et al. Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine. Food Chem Toxicol. 2023;181: e114065.","journal-title":"Food Chem Toxicol"},{"key":"5516_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1046\/j.1365-2125.2002.01696.x","volume":"54","author":"G Lef\u00e8vre","year":"2002","unstructured":"Lef\u00e8vre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Brit J Clin Pharmacol. 2002;54:485\u201392.","journal-title":"Brit J Clin Pharmacol"},{"key":"5516_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00228-002-0426-9","volume":"58","author":"M Thapar","year":"2002","unstructured":"Thapar M, Ashton M, Lindeg\u00e5rdh N, Bergqvist Y, Nivelius S, Johansson I, et al. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol. 2002;58:19\u201327.","journal-title":"Eur J Clin Pharmacol"},{"key":"5516_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00228-002-0424-y","volume":"58","author":"J Miller","year":"2002","unstructured":"Miller J, Trepanier L. Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation. Eur J Clin Pharmacol. 2002;58:69\u201372.","journal-title":"Eur J Clin Pharmacol"},{"key":"5516_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00228-003-0636-9","volume":"59","author":"X Li","year":"2003","unstructured":"Li X, Bj\u00f6rkman A, Andersson T, Gustafsson L, Masimirembwa C. Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003;59:429\u201342.","journal-title":"Eur J Clin Pharmacol"},{"key":"5516_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-270","volume":"11","author":"S Croft","year":"2012","unstructured":"Croft S, Duparc S, Arbe-Barnes S, Craft J, Shin C, Fleckenstein L, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar J. 2012;11: e270.","journal-title":"Malar J"},{"key":"5516_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1590\/S0037-86821991000200008","volume":"24","author":"B Barraviera","year":"1991","unstructured":"Barraviera B, Pereira P, Machado J, De Souza M, Lima C, Curi P, et al. Isoniazid acetylating phenotype in patients with paracoccidioidomycosis and its relationship with serum sulfadoxin levels, glucose-6-phosphate dehydrogenase and glutathione reductase activities. Rev Soc Brasil Med Trop. 1991;24:111\u20134.","journal-title":"Rev Soc Brasil Med Trop."},{"key":"5516_CR26","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1124\/dmd.111.040352","volume":"39","author":"M Honda","year":"2011","unstructured":"Honda M, Muroi Y, Tamaki Y, Saigusa D, Suzuki N, Tomioka Y, et al. Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether. Drug Metab Dispos. 2011;39:1860\u20135.","journal-title":"Drug Metab Dispos"},{"key":"5516_CR27","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1128\/AAC.00343-15","volume":"59","author":"C Vuong","year":"2015","unstructured":"Vuong C, Xie L, Potter B, Zhang J, Zhang P, Duan D, et al. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59:3864\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"5516_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1124\/jpet.300.2.399","volume":"300","author":"X Li","year":"2002","unstructured":"Li X, Bj\u00f6rkman A, Andersson T, Ridderstr\u00f6m M, Masimirembwa C. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002;300:399\u2013407.","journal-title":"J Pharmacol Exp Ther"},{"key":"5516_CR29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1124\/dmd.30.9.1005","volume":"30","author":"K Ilett","year":"2002","unstructured":"Ilett K, Ethell B, Maggs J, Davis T, Batty K, Burchell B, et al. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos. 2002;30:1005\u201312.","journal-title":"Drug Metab Dispos"},{"key":"5516_CR30","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1128\/AAC.00015-15","volume":"59","author":"B Potter","year":"2015","unstructured":"Potter B, Xie L, Vuong C, Zhang J, Zhang P, Duan D, et al. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59:2380\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"5516_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/004982598239597","volume":"28","author":"Z Zeng","year":"1998","unstructured":"Zeng Z, Andrew N, Arison B, Luffer-Atlas D, Wang R. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998;28:313\u201321.","journal-title":"Xenobiotica"},{"key":"5516_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.712","volume":"9","author":"P Tipthara","year":"2021","unstructured":"Tipthara P, Kobylinski K, Godejohann M, Hanboonkunupakarn B, Roth A, Adams J, et al. Identification of the metabolites of ivermectin in humans. Pharmacol Res Perspect. 2021;9: e00712.","journal-title":"Pharmacol Res Perspect"},{"key":"5516_CR33","doi-asserted-by":"publisher","first-page":"e00741","DOI":"10.1128\/AAC.00741-20","volume":"64","author":"P Vanachayangkul","year":"2020","unstructured":"Vanachayangkul P, Im-Erbsin R, Tungtaeng A, Kodchakorn C, Roth A, Adams J, et al. Safety, pharmacokinetics, and activity of high-dose ivermectin and chloroquine against the liver stage of Plasmodium cynomolgi infection in Rhesus macaques. Antimicrob Agents Chemother. 2020;64:e00741-e820.","journal-title":"Antimicrob Agents Chemother"},{"key":"5516_CR34","first-page":"18124","volume":"68","author":"P Vanachayangkul","year":"2024","unstructured":"Vanachayangkul P, Kodchakorn C, Ta-aksorn W, Im-Erbsin R, Tungtaeng A, Tipthara P, et al. Safety, pharmacokinetics, and potential neurological interactions of ivermectin, tafenoquine and chloroquine in Rhesus macaques. Antimicrob Agents Chemother. 2024;68:18124.","journal-title":"Antimicrob Agents Chemother."},{"key":"5516_CR35","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/psp4.13013","volume":"12","author":"N Abla","year":"2023","unstructured":"Abla N, Howgate E, Rowland-Yeo K, Dickins M, Bergagnini-Kolev MC, Chen KF, et al. Development and application of a PBPK modeling strategy to support antimalarial drug development. CPT Pharmacometrics Syst Pharmacol. 2023;12:1335\u201346.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"5516_CR36","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/psp4.12950","volume":"12","author":"K Rowland Yeo","year":"2023","unstructured":"Rowland Yeo K, Wesche D. PBPK modeling of ivermectin - Considerations for the purpose of developing alternative routes to optimize its safety profile. CPT Pharmacometrics Syst Pharmacol. 2023;12:598\u2013609.","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05516-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05516-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05516-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:41:19Z","timestamp":1758739279000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05516-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5516"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05516-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"290"}}